-+ 0.00%
-+ 0.00%
-+ 0.00%

Outlook Therapeutics Secures SMC Approval For LYTENAVA As First And Only Licensed Ophthalmic Bevacizumab For Wet AMD Treatment In UK, Has An Initial 10 Years Of Market Exclusivity From The Date Of Initial Marketing Authorization From The Medicines And Healthcare Products Regulatory Agency

Benzinga·06/10/2025 12:10:21
Listen to the news

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the United Kingdom (UK) and has an initial 10 years of market exclusivity from the date of initial marketing authorization from the Medicines and Healthcare products Regulatory Agency.